Press "Enter" to skip to content

Advaxis bails on late-stage study of AXAL in cervical cancer; shares down 4% – Seeking Alpha

admin 0

Advaxis bails on late-stage study of AXAL in cervical cancer; shares down 4%  Seeking Alpha

Citing a sharpened focus on neoantigen-directed immunotherapies, Advaxis (ADXS -4.4%) announces that it will terminate its Phase 3 AIM2CERV trial …

“cervical cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *